Fourth HIV & hepatitis coinfection workshop; June 19-21, 2008; Madrid, Spain

HIV Clinical Trials

Volumn 10, Issue 1, 2009, Pages 52-62

  Soriano, Vincent ^a   Peters, Marion ^b   Rockstroh, Juergen ^c  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; PEGINTERFERON ALPHA2A; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; RITONAVIR PLUS TIPRANAVIR; TENOFOVIR;

ACUTE HEPATITIS; CLINICAL TRIAL; CONFERENCE PAPER; DELTA AGENT HEPATITIS; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION; LIVER DISEASE; LIVER FIBROSIS; LIVER TOXICITY; MIXED INFECTION; PRIORITY JOURNAL; SIDE EFFECT; SPAIN; VIRUS HEPATITIS;

EID: 64949093496     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1001-52     Document Type: Conference Paper

References (57)

1. Soriano V, Puoti M, Peters M, et al. Care of HIV patients with chronic hepatitis B: Updated recommendations from the HIV-Hepatitis B virus International Panel. AIDS. 2008;22:1399-1410.
2. Chang J, Sirivichayakul S, Avihingsanon A, et al. The combined effects of HIV-1 and HBeAg on the adaptive immune response in chronic HBV infection. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 6.
3. Iser D, Solomon A, Saleh S, et al. HIV infection of chronically HBV-infected human hepatic and stellate cell lines: Implications for pathogenesis of HIV-HBV co-infection. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 7.
4. Bottecchia M, Tuma P, Sheldon J, et al. Natural polymorphisms at the HBV polymerase: Genotypedependence and impact on treatment response. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 17.
5. Vairo F, Iaconi F, Solmone M, et al. Analysis of HBV lamivudine- resistant mutations in a cohort of HBV-infected subjects with or without HIV coinfection. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 18.
6. Matthews G, Batholomeusz A, Locarnini S, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV infected individuals on extended lamivudine therapy. AIDS. 2006;20:863-870.
7. Sheldon J, Soriano V. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother. 2008;61:766-768.
8. Teixeira T, Martin-Carbonero L, Castellares C, et al. Liver fi brosis progression in HIV patients with chronic hepatitis B in the HAART era - a 24 months follow-up study. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 64.
9. Rodger A, Geretti AM, Garcia-Diaz A, et al. Long-term effi cacy and safety of tenofovir in HIV/HBV co-infected patients in a clinical setting. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 66.
10. Nazareth C, Corte-real R, Germano I, et al. Virologic response in HIV/HBV coinfected patients treated with HAART. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 68.
11. Morsica G, Alagna L, Bagaglio S, Lazzarin A, Uberti-Foppa C. Virologic response to Truvada in lamivudine/tenofovir experienced HIV/HBV-coinfected patients. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 69.
12. Grunhage F, Wasmuth J, Vidovic N, et al. No difference in liver fi brosis in a cohort of HIV/HCV-coinfected patients on HAART as compared to HIV-negative HCV patients assessed by transient elastography. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 8.
13. Nuñez-Fernandez C, Martin-Carbonero L, Valencia E, Gonzalez-Lahoz J, Soriano V. The rate of liver-related complications has reached a plateau as cause of hospital admission and death in HIV-infected patients in Madrid. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 38.
14. Macias J, Berenguer J, Arizcorreta A, et al. Fast fi brosis progression observed between sequential liver biopsies in HIV/HCV-coinfected patients. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 9.
15. Nuñez M, Miralles C, Berdun MA, et al. Role of weightbased ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: The PRESCO trial. AIDS Res Hum Retroviruses. 2007;23:972-982.
16. Dixit N, Layden-Almer J, Layden T, Perelson A. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature. 2004;432:922-924.
17. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology. 2005;41:275-279.
18. Labarga P, Barreiro P, Guardiola JM, et al. Early virological effi cacy and hematological safety of pegIFN alpha-2a plus high doses of ribavirin in HIV/HCV-coinfected patients (PERICO study). In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 15.
19. Labarga P, Barreiro P, Vispo E, et al. Ribavirin plasma levels are predictive of HCV clearance after rescue therapy with peg-interferon alpha-2a plus eight-adjusted ribavirin in HIV/HCV-coinfected patients. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 13.
20. Dominguez S, Cassard B, Peytavin G, et al. Early therapeutic drug monitoring of ribavirin is predictive of tolerability and sustained virological response in HIV/HCV-coinfected patients. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 41.
21. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS. 2007;21:1073-1089.
22. Rockstroh J, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med. 2008;9: 82-88.
23. Tuma P, Vispo E, Camacho A, et al. Peginterferon alpha- 2b plus weight-adjusted ribavirin in HIV-infected patients with chronic hepatitis C: Planned interim analysis of the EXTENT study at week 12. In: Program and abstracts of 60 HIV CLINICAL TRIALS · 10/1 · JAN-FEB 2009 the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 45.
24. Vispo E, Tuma P, Maida I, et al. Benefi t of irbesartan or a second course of peginterferon plus ribavirin in prior nonresponders with HIV/HCV coinfection and advanced liver disease. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 52.
25. Fox J, Nastouli E, Thomson E, et al. Increasing incidence of acute hepatitis C in individuals diagnosed with primary HIV in the United Kingdom. AIDS. 2008;22:666-668.
26. Fierer D, Uriel A, Carriero D, et al. Liver fi brosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: A prospective cohort study. J Infect Dis. In press.
27. Gallotta G, Galli L, de Bona A, et al. Acute hepatitis C in HIV co-infected men who have sex with men: Milan, 1996-2007. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 47.
28. Jones R, Low E, Rodger A, et al. Hepatitis C viraemia following sustained virological response to pegylated interferon and ribavirin in HIV-positive men who have sex with men - reinfection or late relapse? In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 12.
29. Shores N, Maida I, Soriano V, Nuñez M. Predictive factors of spontaneous HCV clearance in HIV-infected patients. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 50.
30. Madejon A, Gaeta G, Bottecchia M, Rios P, Garcia-Samaniego J, Soriano V. Assessment of delta viremia in patients with chronic hepatitis delta - influence of HIV infection and antiviral therapy. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 19.
31. Madejon A, Bottecchia M, Garcia-Samaniego J, Rios P, Romero M, Soriano V. Differential replicative behaviour of hepatitis B virus genotypes in patients with chronic hepatitis delta. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 76.
32. Panos G, Holmes P, Mandalia S, et al. Determination of transient elastography cutoff values in Kilopascal for the detection of signifi cant hepatic fi brosis through a systemic review and meta-analysis. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 25.
33. Rodgers A, Fernandez T, Dusheiko G, Jonhson M, Bhagani S. Assessment of staging of liver fi brosis by transient elastography and FIB-4 in HIV patients with chronic liver disease using liver biopsy as the gold standard. Does concordance improve management? In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 3.
34. Recio E, Macias J, Merchante N, et al. Usefulness of liver stiffness to predict esophageal varices requiring therapy in HIV/HCV coinfected patients with cirrhosis. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 20.
35. del Valle J, Camacho A, Mira J, et al. Evolution of liver stiffness evaluated by transient elastometry in patients treated with pegylated interferon plus ribavirin. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 21.
36. Halfon P, Carrat F, Bedossa P, et al. Impact of antiviral treatment on non-invasive predictors of liver fibrosis in HIV/HCV coinfected patients: The Fibrovic 2 study - ANRS HC02. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 16.
37. Soriano V, Puoti M, Garcia-Gasco P, et al. Antiretroviral drugs and liver injury. AIDS. 2008;22:1-13.
38. Nasta P, Gatti F, Borghi F, et al. Fosamprenavir/ritonavir and darunavir/ritonavir based HAART hepatic toxicity in HIV/HCV co-infected subjects with or without cirrhosis. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 33.
39. Macias J, Orihuela F, Rivero A, et al. Liver tolerability of tipranavir plus ritonavir-containing HAART: Influence of hepatitis virus coinfection and pre-existing fibrosis. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 35.
40. Rodriguez-Novoa S, Morello J, Gonzalez M, et al. Increase in bilirubin in HIV/HCV-coinfected patients on stable atazanavir therapy following initiation of peginterferon plus ribavirin. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 49.
41. Barreiro P, Rodriguez-Novoa S, Labarga P, et al. Infl uence of liver fi brosis on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. J Infect Dis. 2007;195:973-979.
42. Veronese L, Rautaureau J, Sadler B, et al. Single-dose pharmacokinetics of amprenavir, a HIV-1 protease inhibitor, in subjects with normal or impaired hepatic function. Antimicrob Agents Chemother. 2000;44:821-826.
43. Gatti F, Nasta P, Lorengian A, et al. Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment for HCVrelated cirrhosis. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract LB-01.
44. Guaraldi G, Squillace N, Stentarelli C, et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: Prevalence, characteristics and predictors. Clin Infect Dis. 2008;47:250-257.
45. Clark J. The epidemiology of non-alcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006;40(Suppl 1): 5-10.
46. Merchante N, del Valle J, Mira J, et al. Insulin resistance is associated with liver stiffness in HIV/HCV coinfected patients. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 1.
47. Bruno R, Sacchi P, Maiocchi L, et al. Correlation among liver stiffness, FIB-4 and metabolic parameters in patients with HIV and hepatitis C virus coinfection. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 4.
48. Cacoub P, Carrat F, Bedossa P, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in HIV-HCV co-infected patients: HOMAVIC-ANRS HC-02 study. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 2.
49. Nasta P, Gatti F, Borghi F, et al. Metabolic profi le is a key factor for virologic success of peginterferon alpha 2a/ ribavirin treatment in HIV/HCV co-infected patients. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 37.
50. Maida I, Nuñez M, Rios MJ, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defi c Syndr. 2006;42:177-182.
51. Mallet V, Blanchard P, Verkarre V, et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS. 2007;21:187-192.
52. Schiano T, Kotler D, Ferran E, Fiel M. Hepatoportal sclerosis as a cause of non-cirrhotic portal hypertension in patients with HIV. Am J Gastroenterol. 2007;102:2356-2540.
53. Maida I, García-Gascó P, Sotgiu G, et al. Antiretroviralassociated portal hypertension: A new clinical condition? Prevalence, predictors and outcome. Antivir Ther. 2008;13:103-107.
54. Saifee S, Joelson D, Braude J, et al. Noncirrhotic portal hypertension in patients with HIV infection. Clin Gastroenterol Hepatol. 2008;6:1167-1169.
55. Maida I, Vispo ME, Sotgiu G, et al. Severe portal hypertension in HIV patients with no primary liver disease: Prevalence, histology and potential etiology. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 10.
56. Panos G, Holmes P, Valero S, et al. Cryptogenic pseudocirrhosis: A new clinical syndrome of non-cirrhotic portal hypertension (unassociated with advanced fibrosis) in patients with HIV that can be detected by transient elastography in differential diagnosis from HCV coinfection. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 24.
57. Vispo E, Maida I, Barreiro P, Moreno V, Soriano V. Upper gastrointestinal bleeding may unmask didanosineassociated portal hepatopathy in HIV/HCV co-infected patients. In: Program and abstracts of the 4th International Coinfection Workshop; June 19-21, 2008; Madrid, Spain. Abstract 11.